Vericel Corporation (NASDAQ:VCEL) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
As disclosed in the Original Report, on May9, 2017, the Company
entered into the License Agreement and the Side Letter. The
Company is eligible to receive from Innovative Cellular
Therapeutics Co., LTD. up to an aggregate of $7,750,000 for
milestone payments related to development and commercialization
in greater China (including mainland China, Taiwan, Hong Kong and
Macau), South Korea, Vietnam, Laos, Cambodia, Thailand, Myanmar,
Malaysia, Indonesia, East Timor, Philippines, Brunei and
Singapore. The descriptions of the License Agreement and the Side
Letter included in the Original Report are otherwise hereby
incorporated by reference into this Form8-K/A. The License
Agreement and the Side Letter are attached to this Form8-K/A as
Exhibits 10.2 and 10.3, respectively.
Item 3.02 Unregistered Sale of Equity
Securities.
The information set forth in Item 3.02 of the Original Report is
incorporated by reference as if fully set forth herein.
Item 7.01 Regulation FD Disclosure.
The information set forth in Item 7.01 of the Original Report is
incorporated by reference as if fully set forth herein.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
|
ExhibitNo. |
|
Description |
|
10.1 * |
Formof Warrant issued by the Company to ICT |
|
|
10.2 * |
License Agreement between Vericel Corporation and |
|
|
10.3 * |
Side Letter between Vericel Corporation and (Innovative |
|
|
99.1 |
Press Release dated May10, 2017 |
* Confidential treatment has been requested for portions of this
exhibit. These portions have been omitted from the exhibit to
this Current Report on Form8-K/A and submitted separately to the
Securities and Exchange Commission.
Filed herewith.
Previously filed.
About Vericel Corporation (NASDAQ:VCEL)
Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy. Vericel Corporation (NASDAQ:VCEL) Recent Trading Information
Vericel Corporation (NASDAQ:VCEL) closed its last trading session up +0.03 at 3.03 with 424,176 shares trading hands.